Last reviewed · How we verify

NCT06739330

Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease

Recruiting now Last updated 20 December 2024
What this trial tests

trial testing Fibroscan in Thyroid Dysfunction in 150 participants. Currently enrolling.

Timeline
19 December 2024
Primary endpoint
1 May 2025
1 May 2025

Quick facts

Lead sponsorTanta University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment150
Start date19 December 2024
Primary completion1 May 2025
Estimated completion1 May 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

18 and older, any sex, with Thyroid Dysfunction or Metabolic Dysfunction-Associated Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Fibroscan

Trials testing the same drug.

Other recruiting trials for Thyroid Dysfunction

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06739330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing